Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2015-12-22 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Galapagos NV. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock options or warrants. The document includes details about the securities to be registered, calculation of registration fees, incorporation by reference of other filings, indemnification of directors and officers, and exhibits related to the registration. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (14,702 characters), and it is not merely an announcement or a short notice, confirming it is a full regulatory filing.
2015-12-22 English
GALAPAGOS EN GILEAD KONDIGEN WERELDWIJDE SAMENWERKING AAN OM FILGOTINIB TE ONTWIKKELEN VOOR DE BEHANDELING VAN REUMA EN ANDERE ONTSTEKINGSZIEKTES
Regulatory Filings Classification · 95% confidence The document is a press release dated December 17, 2015, announcing a global collaboration between Galapagos NV and Gilead Sciences regarding the drug filgotinib. It details financial terms (upfront payment, milestones, royalties), development plans (Phase 3 studies), and includes contact information and extensive forward-looking statements referencing SEC filings (like Form 10-Q for Gilead). This structure—a formal announcement of a significant business event (partnership/financing) released to the public and media, often preceding a formal regulatory filing—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on a major business development and financial implications, but is not a full financial report (10-K or IR), nor a specific management discussion (MDA), nor a capital structure change announcement (CAP, which usually relates to issuing shares/debt), it fits best as an initial announcement of material information. Given the content is a detailed press release about a major strategic event, it is classified as an Earnings Release (ER) as these often cover significant corporate news beyond just quarterly results, or RNS as a general regulatory announcement. However, because it details financial outcomes of the deal and is a formal announcement, ER is often used for such material news releases. Since it is not explicitly an earnings report, RNS is a safer fallback, but the content strongly suggests a major corporate event announcement. Given the context of major partnership and financing details, and the presence of a scheduled conference call, it functions similarly to an Earnings Release announcing key operational/financial news. I will classify it as ER because it is a comprehensive announcement of a material event with financial impact, often released concurrently with or instead of a standard earnings report when major news breaks. If it were purely a regulatory notice without financial detail, RNS would be better. The presence of a conference call suggests it's a primary communication event.
2015-12-17 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It references a press release attached as Exhibit 99.1 but does not contain detailed financial statements or substantive financial data itself. The document length is short (1502 characters), and it primarily serves as a regulatory announcement of the press release issuance. According to the rules, such filings that announce or attach other reports without containing the report itself should be classified as Regulatory Filings (RNS).
2015-12-17 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of December 2015. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release dated December 7, 2015, but does not contain detailed financial statements or substantive financial data. The document length is only 1500 characters, indicating it is a brief report or announcement rather than a full financial report. According to the classification rules, such filings are best categorized under Regulatory Filings (RNS) as they do not fit into other specific report categories and are not full annual or interim reports.
2015-12-15 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of December 2015. Form 6-K is a report of foreign private issuers pursuant to SEC rules and typically contains current reports or press releases but is not a full annual or quarterly report. The document mentions an attached press release as Exhibit 99.1, indicating it is a regulatory filing providing information updates rather than a full financial report. The document length is only 1500 characters, which is short and consistent with a regulatory filing rather than a detailed report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-12-15 English
Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's disease
Earnings Release Classification · 95% confidence The document is dated December 7, 2015, and announces positive interim results from the FITZROY phase 2 study for the drug Filgotinib in Crohn's disease. It highlights key efficacy data (48% clinical remission rate vs. placebo) and safety profile. Crucially, it mentions that a 'Webcast presentation of the results to be held tomorrow' and provides conference call details. The document itself is a press release announcing clinical trial data and the upcoming presentation/call, not the full financial report (10-K), the comprehensive quarterly report (IR), or the presentation slides themselves (IP). This structure—announcing results and scheduling a call/webcast—is characteristic of an Earnings Release (ER) or a general announcement of significant news. Since it focuses purely on clinical trial results and not quarterly financial performance metrics (like revenue, EPS, etc.), it fits best as a major corporate/scientific announcement. Given the options, 'Earnings Release (ER)' is the closest fit for a time-sensitive announcement of key performance indicators (in this case, clinical trial endpoints), although 'Regulatory Filings (RNS)' could also apply if it were a less specific announcement. However, the structure strongly mirrors a typical press release accompanying earnings or major data readouts, which is categorized as ER. Q4 2015
2015-12-08 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.